TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
abrdn plc acquired a new stake in TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the 4th quarter, Holdings Channel.com reports. The firm acquired 200,000 shares of the company’s stock, valued at approximately $1,166,000. Separately, Pale Fire Capital SE bought a new stake in shares of TScan Therapeutics during the 3rd quarter valued at $42,000. […]
Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report released on Tuesday, Benzinga reports. They currently have a $10.00 price target on the stock. Separately, HC Wainwright reissued a buy rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note […]
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.